Compare Gilead Sciences, Inc. (GILD) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Hut 8 Corp — how do they compare? Gilead Sciences, Inc. trades at $149.95 (market cap $182.40B), while Hut 8 Corp trades at $81.37 (market cap $9.82B). The key difference: Gilead Sciences, Inc. is far larger — about 18.6× Hut 8 Corp's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Hut 8 Corp for 11 Days on average.
| GILD | HUT | |
|---|---|---|
Market Cap | $182.40B | $9.82B |
Volume | 4,469,821 | 10,272,678 |
Sector | Health | Financials |
52-Week High | $155.80 | $133.02 |
52-Week Low | $116.74 | $33.76 |
Typical Hold Time | 111 Days | 11 Days |
Enterprise Value | $205.46B | $17.25B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
HUT's stock trades at $80.25, down 10.13% over 24 hours, reflecting bearish technical signals amid weak financials. The company reported a net loss of $226.15 million for 2025, with negative cash flow from operations, though it secured a $1.07 billion credit facility to bolster liquidity. Analyst consensus remains strongly bullish with a $162.69 price target, driven by optimism around its AI infrastructure contracts.
The outlook hinges on HUT's ability to monetize its AI data center pipeline and achieve profitability. Key risks include persistent losses, high debt levels, and execution challenges in a competitive market. The stock offers high-reward potential if the company delivers on its growth strategy, but investors face significant downside if operational improvements falter.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
